Ratings Intellia Therapeutics, Inc.

Equities

NTLA

US45826J1051

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-07 pm EDT			5-day change	1st Jan Change
22.73 ^USD	-0.96%		+6.31%	-25.45%

Jun. 03	Intellia Therapeutics Shares Rise as NTLA-2002 Phase 1 Study Observes 98% Mean Reduction in Monthly Attack Rate	MT
Jun. 03	Transcript : Intellia Therapeutics, Inc. - Special Call

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
The company's "enterprise value to sales" ratio is among the highest in the world.
The company appears highly valued given the size of its balance sheet.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
INTELLIA THERAPEUTICS, INC.	-25.45%	2.19B	B-
MODERNA, INC.	+51.85%	57.87B	B-
LONZA GROUP AG	+41.42%	40.25B	A
IQVIA HOLDINGS INC.	-5.25%	39.94B	B
CELLTRION, INC.	-5.16%	28.54B	C
ICON PUBLIC LIMITED COMPANY	+12.79%	26.4B	B-
ALNYLAM PHARMACEUTICALS, INC.	-20.18%	19.33B	B
MEDPACE HOLDINGS, INC.	+30.88%	12.4B	C+
BIO-TECHNE CORPORATION	+0.61%	12.23B	B+
UNITED THERAPEUTICS CORPORATION	+25.06%	12.2B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes